Janus Henderson Group PLC bought a new position in shares of Stoke Therapeutics (NASDAQ:STOK) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 400,000 shares of the company’s stock, valued at approximately $11,668,000. Janus Henderson Group PLC owned approximately 1.27% of Stoke Therapeutics as of its most recent filing with the Securities and Exchange Commission.
Shares of Stoke Therapeutics stock opened at $35.55 on Monday. The business has a fifty day moving average price of $29.47. Stoke Therapeutics has a 1-year low of $22.01 and a 1-year high of $39.04.
Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($1.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.96) by ($0.58). Research analysts anticipate that Stoke Therapeutics will post -2.24 EPS for the current fiscal year.
In other news, major shareholder Apple Tree Partners Iv, L.P. acquired 1,388,889 shares of Stoke Therapeutics stock in a transaction dated Friday, June 21st. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $25,000,002.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Rtw Investments, Lp acquired 555,556 shares of Stoke Therapeutics stock in a transaction dated Wednesday, June 19th. The stock was purchased at an average price of $18.00 per share, with a total value of $10,000,008.00. The disclosure for this purchase can be found here.
A number of analysts have issued reports on the stock. JPMorgan Chase & Co. assumed coverage on shares of Stoke Therapeutics in a research note on Monday, July 15th. They issued an “overweight” rating and a $34.00 target price for the company. Credit Suisse Group assumed coverage on shares of Stoke Therapeutics in a research note on Monday, July 15th. They issued an “outperform” rating and a $35.00 target price for the company. Cowen reiterated a “buy” rating on shares of Stoke Therapeutics in a research note on Thursday, August 15th. Finally, Canaccord Genuity assumed coverage on shares of Stoke Therapeutics in a research note on Monday, July 15th. They issued a “buy” rating and a $44.00 target price for the company.
Stoke Therapeutics Company Profile
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.
Featured Story: How to Invest in Stocks with Increasing Dividends
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.